Hallmarks of gastrointestinal neuroendocrine tumours: implications for treatment

被引：41

作者：

Walenkamp, Annemiek ^{[1
]}

Crespo, Guillermo ^{[2
]}

Fierro Maya, Felipe ^{[3
]}

Fossmark, Reidar ^{[4
]}

Igaz, Peter ^{[5
]}

Rinke, Anja ^{[6
]}

Tamagno, Gianluca ^{[7
]}

Vitale, Giovanni ^{[8
,9
]}

Oberg, Kjell ^{[10
]}

Meyer, Tim ^{[11
]}

机构：

[1] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, NL-9713 GZ Groningen, Netherlands

[2] Hosp Univ Burgos, Dept Med Oncol, Burgos 09006, Spain

[3] Natl Canc Inst, Dept Endocrine Oncol, Bogota, Colombia

[4] Norwegian Univ Sci & Technol, Dept Canc Res & Mol Med, N-7491 Trondheim, Norway

[5] Semmelweis Univ, Dept Med 2, H-1088 Budapest, Hungary

[6] Univ Hosp Marburg, Dept Gastroenterol, D-35043 Marburg, Germany

[7] St Columcilles Hosp, Dept Gen Internal Med, Dublin, Ireland

[8] Univ Milan, Dept Clin Sci & Community Hlth DISCCO, Milan, Italy

[9] Ist Auxol Italiano IRCCS, Lab Endocrine & Metab Res, I-20095 Cusano Milanino, MI, Italy

[10] Univ Hosp, Dept Endocrine Oncol, Uppsala, Sweden

[11] UCL, Inst Canc, London WC1E 6BT, England

来源：

关键词：

cancer; neuroendocrine tumours; treatment; tumourigenesis; ENDOTHELIAL GROWTH-FACTOR; PANCREATIC ENDOCRINE TUMORS; SOMATOSTATIN RECEPTOR BIOLOGY; PROTEIN-COUPLED RECEPTORS; REGULATORY T-CELLS; PHASE-II; TELOMERASE ACTIVITY; CARCINOID-TUMORS; MTOR PATHWAY; MICROSATELLITE INSTABILITY;

D O I：

10.1530/ERC-14-0106

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In the past few years, there have been advances in the treatment of neuroendocrine tumours (NETs) and improvements in our understanding of NET biology. However, the benefits to patients have been relatively modest and much remains yet to be done. The 'Hallmarks of Cancer', as defined by Hanahan and Weinberg, provide a conceptual framework for understanding the aberrations that underlie tumourigenesis and to help identify potential targets for therapy. In this study, our objective is to review the major molecular characteristics of NETs, based on the recently modified 'Hallmarks of Cancer', and highlight areas that require further research.

引用

页码：R445 / R460

页数：16

共 50 条

[31] Challenges in the treatment of gastrointestinal tumours
Labianca, R.
Berardi, E.
Malugani, F.
ANNALS OF ONCOLOGY, 2006, 17 : V137 - V141
[32] Chemotherapy and biotherapy in the treatment of neuroendocrine tumours
Öberg, K
ANNALS OF ONCOLOGY, 2001, 12 : S111 - S114
[33] Advances in Radionuclide Treatment for Neuroendocrine Tumours
Lamarca, A.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S23 - S23
[34] Basis for treatment of functioning neuroendocrine tumours
Tomassetti, P
Migliori, M
Campana, D
Brocchi, E
Piscitelli, L
Salomone, T
Corinaldesi, R
DIGESTIVE AND LIVER DISEASE, 2004, 36 : S35 - S41
[35] New Perspectives in the Treatment of Neuroendocrine Tumours
Bajetta, Emilio
Catena, Laura
Valente, Monica
Bianco, Nadia
Bellomo, Fernanda
Bombardieri, Emilio
ANTICANCER RESEARCH, 2012, 32 (10) : 4193 - 4200
[36] Diagnosis and treatment of gastric neuroendocrine tumours
Ploekinger, Ursula
WIENER KLINISCHE WOCHENSCHRIFT, 2007, 119 (19-20) : 570 - 572
[37] Treatment strategy of digestive neuroendocrine tumours
Mitry, E.
ONCOLOGIE, 2013, 15 (10-11) : 529 - 532
[38] Molecular insights into gastrointestinal neuroendocrine tumours: importance and recent advances
Corleto, VD
Delle Fave, G
Jensen, RT
DIGESTIVE AND LIVER DISEASE, 2002, 34 (09) : 668 - 680
[39] CD99 immunoreactivity in gastrointestinal and pulmonary neuroendocrine tumours
G. Pelosi
Filippo Fraggetta
Angelica Sonzogni
Nicola Fazio
Alessandra Cavallon
Giuseppe Viale
Virchows Archiv, 2000, 437 : 270 - 274
[40] Expression of class III β-tubulin in neuroendocrine tumours of gastrointestinal tract
Jirásek, T
Mandys, V
Viklicky, V
FOLIA HISTOCHEMICA ET CYTOBIOLOGICA, 2002, 40 (03) : 305 - 309

← 1 2 3 4 5 →